HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT) Files An 8-K Regulation FD Disclosure
Item7.01 Regulation FD Disclosure
On May15, 2017, Helius Medical Technologies, Inc. (the Company)
posted an updated corporate fact sheet to its website at
http://heliusmedical.com/index.php/investor-relations/overview,
which the Company may use from time to time in communications or
conferences. A copy of the corporate fact sheet is attached as
Exhibit99.1 to this Current Report on Form8-K (this Report).
The information in
this Report, including Exhibit99.1 hereto, is furnished to
Item7.01 and shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that Section,
nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such
a filing. The Companys submission of this Report shall not be
deemed an admission as to the materiality of any information
required to be disclosed solely to satisfy the requirements of
Regulation FD.
This Report and
Exhibit99.1 hereto contain forward-looking statements within the
meaning of the federal securities laws. These forward looking
statements are based on current expectations and are not
guarantees of future performance. Further, the forward-looking
statements are subject to the limitations listed in Exhibit99.1
and in the other reports of the Company filed with the Securities
and Exchange Commission, including that actual events or results
may differ materially from those in the forward-looking
statements.
Item9.01.
Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit Number |
ExhibitDescription |
|
| 99.1 | Corporate Fact Sheet, dated May15, 2017 |
2
About HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT)
Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain’s ability to compensate for damage due to trauma or disease. The Company’s PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue. HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT) Recent Trading Information
HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT) closed its last trading session up +0.02 at 1.45 with 21,500 shares trading hands.